Third-line Therapy for metastatic Renal cell carcinoma

被引：0
|
作者：
Rexer, H. [1 ]
机构：
[1] MeckEvidence Geschaftsstelle AUO, D-17252 Schwarz, Germany
来源：
ONKOLOGE | 2011年 / 17卷 / 12期
关键词：
D O I：
10.1007/s00761-011-2173-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1161 / 1162
页数：2
相关论文
共 50 条
  • [41] Enzalutamide effective as third-line therapy
    [J]. Nature Reviews Urology, 2014, 11 (2) : 67 - 67
  • [42] Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
    Gaulin, J.
    Kotb, R.
    Turcotte, E.
    Berard, G.
    Sawan, B.
    Schmutz, G.
    Beauregard, P.
    [J]. CURRENT ONCOLOGY, 2009, 16 (05) : 331 - 333
  • [43] Refining the Use and Sequencing of Third-Line Therapy in Patients With Metastatic Colorectal Cancer
    Grothey, Axel
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 7 - 14
  • [44] Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Tachibana, Hidekazu
    Yoshida, Kazuhiko
    Omae, Kenji
    Iizuka, Junpei
    Kobayashi, Hirohito
    Tanabe, Kazunari
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 559 - 567
  • [45] Axitinib as first-line therapy in metastatic renal cell carcinoma
    Nozawa, Masahiro
    Uemura, Hirotsugu
    [J]. TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 555 - 557
  • [46] Tolerability of first-line therapy for metastatic renal cell carcinoma
    Porta, Camillo
    Szczylik, Cezary
    [J]. CANCER TREATMENT REVIEWS, 2009, 35 (03) : 297 - 307
  • [47] Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy
    Hiroki Ishihara
    Toshio Takagi
    Tsunenori Kondo
    Hidekazu Tachibana
    Kazuhiko Yoshida
    Kenji Omae
    Junpei Iizuka
    Hirohito Kobayashi
    Kazunari Tanabe
    [J]. International Journal of Clinical Oncology, 2018, 23 : 559 - 567
  • [48] Third-line therapy and beyond for patients with advanced/metastatic non-small cell lung cancer (NSCLC).
    Corral Jaime, Jesus
    Gonzalez de la Pena, Miriam
    Alonso, Miriam
    Sanchez Gastaldo, Amparo
    Dolores Mediano, Maria
    Amerigo, Marta
    Enrique Robles, Carlos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Third line therapy in metastatic renal cell carcinoma (mRCC): results from the international mRCC database consortium (IMDC)
    Stukalina, Igor
    Wellsa, J. Connor
    Donskovb, Frede
    Rinic, Brian I.
    Leed, Jae-Lyun
    Bjarnasone, Georg A.
    Beuselinckf, Benoit
    Smoragiewicz, Martin
    Alvah, Ajjai Shivaram
    Srinivasi, Sandy
    Woodi, Lori
    Saleemk, Sadia
    Pal, Sumanta Kumar
    Yuasam, Takeshi
    Broomn, Reuben James
    Kanesvaran, Ravindran
    Bamiasp, Aristotelis
    Knoxq, Jennifer J.
    Henga, Daniel Y. C.
    Choueirir, Toni K.
    [J]. BJU INTERNATIONAL, 2015, 116 : 21 - 21
  • [50] Metastatic Colorectal Cancer: Strategies for Third-Line Treatment
    Marshall, John L.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 7 - 15
12345